Aided by the growth in pharmaceuticals and consumer products division, Zydus Lifesciences Ltd reported a 39 percent year-on-year growth in net profit at ₹1,258 crore for the second quarter of financial year 2025-26.

The Board of Directors at its meeting held on Thursday approved raising ₹5,000 crore by way of issuance of eligible securities of the company in one or more tranches by way of qualified institutions placements, rights issue, preferential allotment or a private placements, the company told the exchanges.

During the second quarter of FY26 revenue from operations of the company rose by 18 per cent to ₹6,038 crore. Revenues from the pharmaceutical division grew by 15 per cent to ₹5,474 crore, while those from consumer products division increased by 33 per cent to ₹649 crore.

“Ou

See Full Page